El Kendi Pharmaceuticals Manufacturing Company
Quick facts
Phase 3 pipeline
- Nimotuzumab ( h-R3) · Oncology
Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- El Kendi Pharmaceuticals Manufacturing Company portfolio CI brief
- El Kendi Pharmaceuticals Manufacturing Company pipeline updates RSS
Frequently asked questions about El Kendi Pharmaceuticals Manufacturing Company
What is El Kendi Pharmaceuticals Manufacturing Company's pipeline?
El Kendi Pharmaceuticals Manufacturing Company has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Nimotuzumab ( h-R3).
Related
- Sector hub: All tracked pharma companies